/ /

CLINICAL

How to use tear osmolarity to help treat dry eye disease
Investigational wet AMD therapies aim for innovative targetsMany investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Cataract surgery on patients with PXFMom has pseudoexfoliation syndrome (PXF) clinically visible in both eyes. She experiences pops of elevated intraocular pressure (IOP) in one eye and uses glaucoma medications.
Offer options to your cataract patientsAs primary-care optometrists, we are the gatekeepers for baby boomers inquiring about cataract surgery. Today’s patients have treatment options available not only to address their lifestyle complaints but to provide them with better vision and possibly reduced dependence on glasses or contact lenses.
Upgrade your patients to new technologyWith much of the digital revolution occurring after 2008 and most contact lens technology developing well before it, there is an inherent design feature mismatch. The majority of the available contact lenses are not designed for how patients are using their eyes.
Protein agent may change approach to treating dry eye, inflammationRecombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.
Exploring off-label, investigational approaches for allergic conjunctivitisSeasonal and perennial allergic conjunctivitis are common conditions that are not always well-controlled with conventional therapy. Alternative approaches and novel investigational treatments are discussed.
Novel topical peptide for dry eye tackles underlying cause of diseaseA phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating  a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.
Novel neurostimulator device uses nasal cavities to stimulate tearsChronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.